PCSK9i: proprotein convertase subtilisin/kexin type 9 inhibitor a new phase of lipid-lowering treatment

PCSK9i: proprotein convertase subtilisin/kexin type 9 inhibitor a new phase of lipid-lowering treatment

This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2023.

Podrobná bibliografie
Hlavní autor: Lubaba, Anikah
Další autoři: Fariha, Luluel Maknun
Médium: Diplomová práce
Jazyk:English
Vydáno: Brac University 2024
Témata:
Cardiovascular disease
CVD
Cholesterol-lowering therapy
Hyperlipidemia
Monoclonal antibody
PCSK9
Heart > Diseases > Treatment
Coronary heart disease > Treatment
Cholesterol > Pathophysiology
On-line přístup:http://hdl.handle.net/10361/23252

Internet

http://hdl.handle.net/10361/23252

Podobné jednotky